Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. - Wikidata - wikimedia - TriplyDB

Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.

Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.

http://www.wikidata.org/entity/Q35525659

about

Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias Current and future alternative therapies for beta-thalassemia major Sickle cell disease in children Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea Variation in Gamma-Globin Expression before and after Induction with Hydroxyurea Associated with BCL11A, KLF1 and TAL1.Developmental Injury to the Cerebellar Cortex Following Hydroxyurea Treatment in Early Postnatal Life: An Immunohistochemical and Electron Microscopic Study.Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia.Hydroxycarbamide: clinical aspects.Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial.Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia.A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia Current management of sickle cell anemia.Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease.Frequency of Hospitalizations for Pain and Association With Altered Brain Network Connectivity in Sickle Cell Disease.Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics.Hydroxycarbamine: from an Old Drug Used in Malignant Hemopathies to a Current Standard in Sickle Cell Disease.Pediatric perspective on pharmacogenomics.Emerging science of hydroxyurea therapy for pediatric sickle cell disease.Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.Hydroxyurea therapy for sickle cell anemia.Opportunities for model-based precision dosing in the treatment of sickle cell anemia.Effects of Hydroxyurea Exposure on the Rat Cerebellar Neuroepithelium: an Immunohistochemical and Electron Microscopic Study Along the Anteroposterior and Mediolateral Axes.Emerging point-of-care technologies for sickle cell disease screening and monitoring.Clinically-oriented proteomic investigation of sickle cell disease: Opportunities and challenges.An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine.Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the nrf2 pathway.A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.Hydroxyurea Treatment and Development of the Rat Cerebellum: Effects on the Neurogenetic Profiles and Settled Patterns of Purkinje Cells and Deep Cerebellar Nuclei Neurons.Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity.In Vitro Hb Production in B-thalassemia Patients Is Not a Predictor of Clinical Responsiveness to Hydroxyurea Pattern of hemolysis parameters and association with fetal hemoglobin in sickle cell anemia patients in steady state.Sickle cell disease (SCD), iNKT cells, and regadenoson infusion.Pharmacogenomics of sickle cell disease: steps toward personalized medicine.To respond or not to respond to hydroxyurea in thalassemia: a matter of stress adaptation?

P2860

Q24187646-5B097B67-5920-49A9-8A90-BE1253C26DF7 Q26750906-8ADB194C-EBC4-4F33-86D4-5D35D28D7342 Q26864582-3CE2553E-E6C1-40E9-A0F0-7EE986861EB9 Q28544643-53AE8511-D51C-4D12-9AC1-ABE310DD9200 Q33436115-604A1AED-B404-4C6C-A1DB-920B6187DD63 Q34322542-24BA0719-CC61-4B5E-9E5A-5DCBDF33DCA4 Q34586227-9F73FF06-6EA1-4E5F-86EB-F52990D22386 Q35656305-0555236C-64D5-4C08-A6AC-B7E0F26B5194 Q36124772-35FA3B28-896F-4068-9A8A-4A85A7D525B2 Q36155283-CC0AC8E0-69A1-4E9F-9804-5F8A969933A3 Q36239553-0B11CAD7-C217-4E40-B02E-7C007B1F0330 Q36706798-8B7DCE1E-C74A-448B-B2D8-EF038D2DF999 Q36778962-2DDD9702-DE5A-4C57-91FD-7EE933CF6CC8 Q36779445-D049B810-9111-4FE3-B9D8-F97CFECD1004 Q36792555-E5A2F3C2-049C-4340-AEBA-886FCA9BF934 Q36966277-648C6DB7-FCC6-4B21-A8E6-743B9E97B26F Q37040238-FE5F1B8A-28C3-45EF-B7AB-CF9E32ADD895 Q37107206-7306A713-C795-4B27-85A2-46FDA5E26948 Q37179797-97B08E3C-AF8D-4F06-90F3-3A3F25B41202 Q37439697-2A89072A-9613-4493-A072-CAF133B8BC96 Q37677221-DB7703D7-1556-4D2E-83C7-3A249BAC10F2 Q38162869-58C2D917-E288-4809-8D78-3EA68DE5B7F2 Q38164192-682390C2-D1E8-4A12-BCDA-79DC8A19480F Q38243173-A4DA5881-D47A-4B6A-BE92-4B4C48E0ECF7 Q38586282-3296E638-54D3-41F7-98B3-5615656A8F21 Q38642609-23816BCC-DF0E-4475-B983-B5F3DB9058DF Q38661023-6E67A53C-95F6-42C6-AC77-653A8F456C30 Q38804432-65CF1DAC-85C8-407A-A0FD-F60A120DCD1F Q38837694-B3A5F418-21AC-4D5D-B532-05D861A90A17 Q38956275-DDE78425-C8A7-4803-BBB1-4EDB32F65A8D Q39011617-946B393E-73A9-490C-A59E-3987805D9F82 Q39390596-4AD2293B-BEFD-4EFB-B17A-B605A93C8367 Q39442230-4A7A0958-C01C-496A-B8E1-FB99A1C296B7 Q39612583-B15F6DC0-32CF-40CC-90EB-B7980A97CD5D Q40245190-0A78CB87-4353-411A-AE32-FD8C66EEEAA0 Q41466551-DDB95157-284D-44AD-BFCB-287B971C5A03 Q42585891-AEC63B63-DEA7-403E-8F70-ED243C46CFB3 Q42587651-142F9266-A0CB-4BB3-BF18-AE88B43D9D3E Q42964401-36FF938A-8D1B-41A7-9D4B-7891CFD35925 Q42988875-10E3FED2-A34C-492A-8326-347A7100D7A9

P2860

Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.

http://www.wikidata.org/entity/Q35525659

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pharmacokinetics, pharmacodyna ...... ldren with sickle cell anemia.

@ast

Pharmacokinetics, pharmacodyna ...... ldren with sickle cell anemia.

@en

type

label

Pharmacokinetics, pharmacodyna ...... ldren with sickle cell anemia.

@ast

Pharmacokinetics, pharmacodyna ...... ldren with sickle cell anemia.

@en

prefLabel

Pharmacokinetics, pharmacodyna ...... ldren with sickle cell anemia.

@ast

Pharmacokinetics, pharmacodyna ...... ldren with sickle cell anemia.

@en

P1433

Q35525659-DD30DF9E-14B4-4BAB-B972-48067645D3CC

P1476

Q35525659-9411ACB9-1F77-4C6B-BC84-D60CADC92AB2

P2093

Q35525659-23CAD3D9-D587-4762-BDC3-B49FA725E2C7

Q35525659-2E0C5B95-56DC-42A0-9E6B-B31B2D464745

Q35525659-30D19570-B824-46F2-81F9-EA8755F93E84

Q35525659-377F7BF9-7D12-4656-9544-6E595A0CF7B7

Q35525659-7EEDBC1E-308D-4F82-8C49-2D4029F54ACF

Q35525659-86429983-7CEE-4C83-812E-346AC9D648F9

Q35525659-8F5071BB-9B4F-4B65-BC29-4B3B7B898F3E

Q35525659-A1A94149-236E-4E0A-85FD-F831C5E69225

Q35525659-C7575037-DD83-4302-808F-1EE6348DC296

Q35525659-F9C8F018-1DD1-4179-892F-ABB22915EE3F

P2860

Q35525659-03F59D6C-2409-4361-A2DF-E1F975E82A50

Q35525659-0892C5DD-3D83-4E94-AEE9-FC5FA1FBC9AE

Q35525659-0DA8F18B-3FFC-438F-91E6-C86DE44C22AB

Q35525659-18C86500-1E67-4D80-80EC-946331A07AF8

Q35525659-1FD1BF83-0E03-411C-AD74-D9370E9D8688

Q35525659-2DAC5F73-5CB6-4B44-BE4B-1D0EB82E6849

Q35525659-2DC56BE8-B112-40FD-A53E-96036020078D

Q35525659-30C4C014-1A6D-4F49-B48F-BAF0F021ED08

Q35525659-4773B687-1C6E-4A3A-8367-276F9D97206D

Q35525659-4BB9B613-B375-49A4-ACAE-4E8A4DFC2C44

P304

Q35525659-430F054F-68A0-462D-B7FC-E0D7317B87D0

P31

Q35525659-401A6F1D-1A77-4339-A476-15AA66FB2FCF

P356

Q35525659-09CE8C59-46D4-4400-B7EE-C86A7827FF9E

P407

Q35525659-A95DDECA-C82D-4A61-91DE-89EF1E89E082

P433

Q35525659-92ED35D2-8690-400C-B5FB-C50486724E06

P478

Q35525659-39550FA1-BBDF-4984-83BE-A2BE129DDCB6

P50

Q35525659-8D66DB7B-8D1D-4AAE-AB28-AE35E5185427

P577

Q35525659-A414578C-D34C-4ADC-8800-B62F667509B8

P5875

Q35525659-C849D8DE-079E-46F6-9E66-44800BB54693

P698

Q35525659-5F97BF65-1661-4541-A2B0-E4CEC1ED0A7F

P921

Q35525659-A00557BC-A863-4CF7-907E-A27BB91380E5

P932

Q35525659-B6F2C7F6-2969-4373-85EF-C8B5B6BD0D59

P356

BLOOD-2011-07-364190

P1433

P1476

Pharmacokinetics, pharmacodyna ...... ldren with sickle cell anemia.

@en

P2093

Amy C Kimble

http://www.w3.org/2001/XMLSchema#string

Banu Aygun

http://www.w3.org/2001/XMLSchema#string

Jenny M Despotovic

http://www.w3.org/2001/XMLSchema#string

Jin He

http://www.w3.org/2001/XMLSchema#string

Jonathan M Flanagan

http://www.w3.org/2001/XMLSchema#string

Matthew P Smeltzer

http://www.w3.org/2001/XMLSchema#string

Nicole A Mortier

http://www.w3.org/2001/XMLSchema#string

Russell E Ware

http://www.w3.org/2001/XMLSchema#string

Song Wu

http://www.w3.org/2001/XMLSchema#string

Thad Howard

http://www.w3.org/2001/XMLSchema#string

P2860

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.

How I use hydroxyurea to treat young patients with sickle cell anemia.

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?

Glomerular hyperfiltration and albuminuria in children with sickle cell anemia.

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study

Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults.

Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters.

P304

4985-4991

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-07-364190

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Alex Sparreboom

P577

2011-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51604054

http://www.w3.org/2001/XMLSchema#string

P698

21876119

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease

P932

3208303

http://www.w3.org/2001/XMLSchema#string